Novel agents in mantle cell lymphoma Journal Article
| Author: | Kumar, A. |
| Article Title: | Novel agents in mantle cell lymphoma |
| Abstract: | Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma, comprising approximately 6–8 % of all non-Hodgkin lymphomas. MCL is biologically and clinically heterogeneous, and there is no standard treatment for MCL. Although untreated MCL often responds well to frontline combination chemotherapy, relapsed, refractory MCL can be challenging to treat and traditional cytotoxic chemotherapy is typically not highly effective. In recent years, increased insight into the molecular and genomic diversity of MCL and the pathogenesis of the disease has given rise to the development of many new biologically targeted therapies. Ibrutinib was recently FDA approved for relapsed, refractory MCL and will likely have a significant impact on treatment paradigms for MCL. In addition to ibrutinib, there are many classes of novel agents that are currently in development. This review focuses on recent developments in the management of relapsed, refractory MCL, describing the growing armamentarium of novel agents available to combat this disease. © 2015, Springer Science+Business Media New York. |
| Keywords: | treatment response; fludarabine; lenalidomide; prednisone; disease course; drug tolerability; review; cancer recurrence; salvage therapy; cisplatin; doxorubicin; cancer combination chemotherapy; drug safety; nonhuman; treatment duration; drug approval; gemcitabine; cytarabine; rituximab; cell death; cell cycle progression; protein bcl 2; unindexed drug; progression free survival; bortezomib; mantle cell lymphoma; multiple myeloma; bone marrow suppression; protein targeting; thrombocytopenia; bendamustine; cyclophosphamide; dexamethasone; vincristine; autologous stem cell transplantation; waldenstroem macroglobulinemia; phosphatidylinositol 3 kinase; temsirolimus; febrile neutropenia; fever; rash; hypotension; cd20 antigen; nonhodgkin lymphoma; epigenetics; mitoxantrone; flavopiridol; clinical effectiveness; oxaliplatin; cyclin d1; everolimus; carfilzomib; bcl-2 inhibitors; hdac inhibitors; idelalisib; ibrutinib; human; palbociclib; abemaciclib; obinutuzumab; cyclin-dependent kinase (cdk) inhibitors; mechanism-based therapies; phosphatidylinositol-4,5-bisphosphate 3-kinase (pi3k) pathway inhibitors; temosirolimus; venetoclax; refractory cell lymphoma; refractory mantle cell lymphoma; relapsed mantle cell lymphoma |
| Journal Title: | Current Oncology Reports |
| Volume: | 17 |
| Issue: | 8 |
| ISSN: | 1523-3790 |
| Publisher: | Springer |
| Date Published: | 2015-06-01 |
| Start Page: | 34 |
| Language: | English |
| DOI: | 10.1007/s11912-015-0460-2 |
| PROVIDER: | scopus |
| PUBMED: | 26045130 |
| DOI/URL: | |
| Notes: | Export Date: 2 July 2015 -- Source: Scopus |
